Liposomal bupivacaine vs. bupivacaine: same analgesic efficacy and narcotic use after TKA .
Does Extended-Release Liposomal Bupivacaine Better Control Pain Than Bupivacaine After Total Knee Arthroplasty (TKA)? A Prospective, Randomized Clinical Trial
J Arthroplasty. 2015 Sep;30(9 Suppl):64-7111 patients undergoing primary unilateral total knee arthroplasty were randomized to receive a periarticular injection of either liposomal bupivacaine or bupivacaine during surgery, as part of a multimodal analgesic protocol. The purpose of this study was to determine how liposomal bupivacaine compared to bupivacaine injection alone in terms of pain and narcotic use. The results indicated no difference in pain up to 3 days post-operatively between groups. As well, narcotic use, length of hospital stay, nausea, and range of motion, the latter of which was assessed up to 3 weeks postoperatively, were similar between groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
